In this study, we have demonstrated that our novel ferrocene derivative, compound 2 (C16H20FeClNO) translocates K-Ras from the PM to cytosol and endomembranes by elevating cellular ROS, and it blocks the K-Ras/MAPK signaling and the growth of K-Ras-dependent PDAC and NSCLC cells. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.